Charcot-Marie-Tooth neuropagthy (CMT) is one of the most commonly inherited neuromuscular diseases, with prevalence of approximately 1 in 2,500 persons.
Clinical complains are mainly represented by muscle pain, sensation of fatigue and painful muscle cramps. No treatment of clinical symptoms is available yet.
A clinical open trial has been performed in order to evaluate the efficacy of palmitoylethanolamide in 22 patients (7 male and 15 females) from four different CMT families, treated with 1200 mg PEA/day for 80 days
None of the patients had an add-on treatment for the clinical symptoms.
Mean values for muscle pain at decreased from 5.9 ± 2.1 to 3.9 ± 1.7 (p<0.0001),
Scores for fatigue decreased form 6.3 ± 2.4 to 3.4 ± 1.6 (p <0.0001).
Score for painful cramps at T1diminished from 5.4 ± 1.2 to 3.8 ± 1.3 (p<0.0001).
At the end of the trial a more robust decrease for muscle pain, fatigue and painful cramps was observed.
Palmitoylethanolamide seems effective in improving clinical symptoms of CMT neuropathy
Source: Giovanni Antioco Putzu, Neurology and Clinical Neurophysiology, Casa di Cura Sant’Elena, Italy: Title: Palmitoylethanolamide trial on Charcot-Marie-Tooth (CMT) Neuropathy